- Home
- IOVA vs LMB Comparison
IOVA vs LMB Comparison
Compare IOVA & LMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- LMB
- Stock Information
- Founded
- IOVA 2007
- LMB 1901
- Country
- IOVA United States
- LMB United States
- Employees
- IOVA N/A
- LMB N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- LMB Engineering & Construction
- Sector
- IOVA Health Care
- LMB Consumer Discretionary
- Exchange
- IOVA Nasdaq
- LMB Nasdaq
- Market Cap
- IOVA 975.1M
- LMB 1.1B
- IPO Year
- IOVA N/A
- LMB 2014
- Fundamental
- Price
- IOVA $2.47
- LMB $69.65
- Analyst Decision
- IOVA Buy
- LMB Strong Buy
- Analyst Count
- IOVA 12
- LMB 2
- Target Price
- IOVA $10.36
- LMB $144.00
- AVG Volume (30 Days)
- IOVA 20.9M
- LMB 200.8K
- Earning Date
- IOVA 11-06-2025
- LMB 11-04-2025
- Dividend Yield
- IOVA N/A
- LMB N/A
- EPS Growth
- IOVA N/A
- LMB 39.03
- EPS
- IOVA N/A
- LMB 3.03
- Revenue
- IOVA $250,425,000.00
- LMB $603,582,000.00
- Revenue This Year
- IOVA $65.15
- LMB $28.57
- Revenue Next Year
- IOVA $58.47
- LMB $14.48
- P/E Ratio
- IOVA N/A
- LMB $22.79
- Revenue Growth
- IOVA 175.62
- LMB 16.56
- 52 Week Low
- IOVA $1.64
- LMB $63.02
- 52 Week High
- IOVA $9.70
- LMB $154.05
- Technical
- Relative Strength Index (RSI)
- IOVA 57.23
- LMB 30.58
- Support Level
- IOVA $2.09
- LMB $65.25
- Resistance Level
- IOVA $2.55
- LMB $70.78
- Average True Range (ATR)
- IOVA 0.24
- LMB 3.69
- MACD
- IOVA 0.01
- LMB -0.51
- Stochastic Oscillator
- IOVA 61.59
- LMB 18.68
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.